Pharmaceutical Research

, Volume 27, Issue 11, pp 2365–2373 | Cite as

Old and New Molecular Mechanisms Associated with Platelet Resistance to Antithrombotics

  • Antonio J. López Farré
  • Juan Tamargo
  • Petra J. Mateos-Cáceres
  • Luís Azcona
  • Carlos Macaya
Expert Review


Current available data show that about 5 to 40% of coronary patients treated with conventional doses of antithrombotic drugs do not display adequate antiplatelet response. Nowadays, aspirin remains the main antiplatelet therapy. However, a significant number of patients show platelet resistance to aspirin therapy, and recurrent thrombotic events occur. Combined antithrombotic therapies with thienopyridines, such as clopidogrel have been used to resolve this problem. However, clopidogrel treatment has been also associated with wide response variability, and non-responsiveness to clopidogrel also occurs in some patients. Therefore, the main question arising about the antithrombotic therapy is why particular patients do not benefit from the therapy and how they might be identified to improve their treatment. Different hypotheses have been suggested, including genetic factors, platelet heterogeneity, non-compliance and others. However, it is probably that many molecular mechanisms involved in platelet resistance to antithrombotic therapies still remains unknown. New technologies, such as proteomics and genetic, are beginning to show new unknown biological biomarkers and molecular mechanisms which may be associated with platelet antithrombotic drug resistance.


antiplatelet agents aspirin resistance proteomics 



Some of the studies here referred have been performed with the help of Heracles Network (Red Heracles RD06/0009/010). Petra J Mateos-Cáceres is staff of Fundación para la Investigación Biomédica del Hospital Clínico San Carlos. Authors thank Begoña Larrea and Miguel Dantart for secretarial assistance.


  1. 1.
    Antithrombotic Trialist´s Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in hihgh risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  2. 2.
    Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationship among dose, effectiveness and side effects. Chest. 2001;119:39S–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Physician’s Health Study: aspirin and primary prevention of coronary heart disease. N Engl J Med. 1989;321:1825–8.Google Scholar
  4. 4.
    Antiplatelet Trialilst´s Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81–106.Google Scholar
  5. 5.
    ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349–60.Google Scholar
  6. 6.
    López-Farré A, Caramelo C, Esteban A, Alberola ML, Montón M, Millás I, et al. Effects of aspirin on platelets neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation. 1995;91:2080–8.PubMedGoogle Scholar
  7. 7.
    Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E. Aspirin induces nitric oxide release from vascular endothelium in a novel mechanism of action. Br J Pharmacol. 2004;143:159–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997;77:333–7.PubMedGoogle Scholar
  9. 9.
    Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin Improves Endothelial Dysfunction in Atherosclerosis. Circulation. 1998;97:716–20.PubMedGoogle Scholar
  10. 10.
    Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safer LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation. 1997;95:63–8.PubMedGoogle Scholar
  11. 11.
    Michelson AD, Cattaneo M, Eikelboom JW, Grubel P, Kottke-Marchant K, Kunicki TJ, et al. Platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis; working group on aspirin resistance. Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost. 2005;3(6):1309–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Harrison P. Progress in the assessment of platelet function. Br J Haematol. 2000;111:73–734.Google Scholar
  13. 13.
    Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non.urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ. 2004;328:477–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004;43:1122–6.CrossRefGoogle Scholar
  16. 16.
    Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397–403.CrossRefPubMedGoogle Scholar
  17. 17.
    Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC. 2003;41:961–5.PubMedGoogle Scholar
  19. 19.
    Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis. 2006;22(2):103–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147:293–300.CrossRefPubMedGoogle Scholar
  21. 21.
    Carney RM, Freeland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24:35–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95:973–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of Aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147:293–300.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose, aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118:723–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849.CrossRefPubMedGoogle Scholar
  26. 26.
    Dunn EJ, Phillipou H, Ariens R, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006;49:1071–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Ajjan R, Grant PJ. Coagulation and atherombotic disease. Atherosclerosis. 2006;186:240–59.CrossRefPubMedGoogle Scholar
  28. 28.
    Rendell M, Nierenberg J, Brannan C, Valentine JL, Stephen PM, Dodds S, et al. Inhibition of glycation of albumin and hemoglobin by acetylation in vitro and in vivo. J Lab Clin Med. 1986;108:286–93.PubMedGoogle Scholar
  29. 29.
    Swamy-Mruthini S, Carter AL. Acetyl-L-carnitine decreases glycation of lens proteins: in vitro studies. Exp Eye Res. 1999;69:109–15.CrossRefGoogle Scholar
  30. 30.
    Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005;83:148–58.CrossRefPubMedGoogle Scholar
  31. 31.
    Hillarp A, Palmquist B, Lethagen S, Villoutreix BO, Mattiasson I. Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res. 2003;112:275–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxigenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73:122–30.CrossRefPubMedGoogle Scholar
  33. 33.
    Mateos-Cáceres PJ, Azcona L, Fernández-Ortiz A, Sacristán D, Bernardo E, Ramos-Mozo P, Alonso-Orgaz S, Fernández-Arquero M, López-Farré A, Macaya C. Proteomics and genetics aspects of aspirin resistance. Trauma Fund MAPFRE. 2008.Google Scholar
  34. 34.
    Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281–9.PubMedGoogle Scholar
  35. 35.
    Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.CrossRefPubMedGoogle Scholar
  36. 36.
    Censarek P, Freídle K, Udelhoven M, Ku SJ, Hohlfeld T, Meyer-Kirchrath JJ, et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost. 2004;92:925–9288.PubMedGoogle Scholar
  37. 37.
    González-Conejero R, Rivera J, Corral J, Acuña C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneus response to aspirin failure? Stroke. 2005;36:276–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Censarek P, Steger G, Paolini C, Hohlfeld T, Grosser T, Zimmermann N, et al. Alternative splicing of platelet cyclooxigenase-2 mRNA in patients after coronary artery bypass grafting. Thromb Haemost. 2007;98:1309–15.PubMedGoogle Scholar
  39. 39.
    Sane DC, McKee SA, Malinin AI, Serebruany VL. Frecuency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol. 2002;90:893–5.CrossRefPubMedGoogle Scholar
  40. 40.
    López-Farré AJ, Mateos-Cáceres PJ, Sacristán D, Azcona L, Bernardo E, Pérez de Prada T, et al. Relationship between vitamina binding protein and aspirin resistance in coronary ischemic patients: A proteomic study. J Proteome Res. 2007;6:2481–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, Ponce De Leon A, et al. Reticulated platelets in acute coronary syndrome: A marker of platelet activity. J Am Coll Cardiol. 2004;44:2091–3.CrossRefPubMedGoogle Scholar
  42. 42.
    Hung J, Lam JYT, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92:2432–6.PubMedGoogle Scholar
  43. 43.
    Nakamura T, Uchiyama S, Yamazaki M, Okubo K, Takakuwa Y, Iwata M. Flow cytometric analysis of reticulated platelets in patients with ischemic stroke. Thromb Res. 2002;106:171–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Guthikonda S, Lev EI, Patel R, Delao T, Bergeron AL, Dong J-F, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. Thromb Haemost. 2007;5:490–6.CrossRefGoogle Scholar
  45. 45.
    Mateos-Cáceres PJ, Macaya C, Azcona L, Modrego J, Mahillo E, Bernardo E, et al. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost. 2010;103(1):160–70.PubMedGoogle Scholar
  46. 46.
    Chen WH, Lee PY, William NG, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting. Am J Neuroradiol. 2008;29:281–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future presperctives. JACC. 2007;49:1505–16.PubMedGoogle Scholar
  49. 49.
    Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J. 2008;156(2 Suppl):S3–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Ferreira IA, Mocking AIM, Feijge MAH, Gorter G, van Haeften TW, Heemskerk JWM, et al. Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2006;26:417–22.CrossRefPubMedGoogle Scholar
  52. 52.
    Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430–6.PubMedGoogle Scholar
  53. 53.
    Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Barrera Ramírez C, Sabaté M, Fernandez C, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weigh adjusted? J Invasive Cardiol. 2004;16:169–74.PubMedGoogle Scholar
  54. 54.
    Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004;109:3064–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000;28:1369–78.PubMedGoogle Scholar
  56. 56.
    Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis. 2001;159:239–41.CrossRefPubMedGoogle Scholar
  57. 57.
    Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol. 2003;92:285–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schömig A, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least4 weeks prior to coronary artery stenting. Eur Heart J. 2004;25:1898–902.CrossRefPubMedGoogle Scholar
  59. 59.
    Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (Optimizing anti-Platelet Therapy In diabetes MellitUS) study. Circulation. 2007;115:708–16.CrossRefPubMedGoogle Scholar
  60. 60.
    Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al. A randomize study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29:2202–11.CrossRefPubMedGoogle Scholar
  61. 61.
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenoses in patients with diabetes mellitus the DECLARE DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug.Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;1181–7.Google Scholar
  62. 62.
    Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366–73.CrossRefPubMedGoogle Scholar
  63. 63.
    Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading and maintenance-dose clopidogrel in patients with planned percutaneus coronary intervention; the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation. Thrombolysis in Myocardical Infarction 44 trial. Circulation. 2007;116:2923–32.CrossRefPubMedGoogle Scholar
  64. 64.
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 plymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Antonio J. López Farré
    • 1
  • Juan Tamargo
    • 2
  • Petra J. Mateos-Cáceres
    • 1
  • Luís Azcona
    • 1
  • Carlos Macaya
    • 1
  1. 1.Cardiovascular Research Unit, Cardiology DepartmentHospital Clínico San CarlosMadridSpain
  2. 2.Pharmacology Department. School of MedicineUniversidad ComplutenseMadridSpain

Personalised recommendations